Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: An overview

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1775-1781

  Kyd, Jennelle M ^a   Cripps, Allan W ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Bacteria; Immunization; Mucosal

Indexed keywords

BACTERIAL VACCINE; CD4 ANTIGEN; CYTOKINE; INACTIVATED VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; HAEMOPHILUS INFLUENZAE; HELPER CELL; IMMUNITY; IMMUNIZATION; INTESTINE LYMPHATIC TISSUE; MORAXELLA CATARRHALIS; MOUSE; MUCOSA; NEUTROPHIL; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL VACCINES; EAR, MIDDLE; HUMANS; IMMUNITY, MUCOSAL; RESPIRATORY SYSTEM; VACCINATION; VACCINES, ATTENUATED;

EID: 0345003930     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00441-1     Document Type: Conference Paper

References (49)

1. Murphy T.F. Branhamella catarrhalis-epidemiology, surface antigenic structure and immune response. Microbiol. Rev. 60:1996;267-279.
2. St Geme J.W. III Nontypable Haemophilus influenzae disease: epidemiology, pathogenesis and prospects for prevention. Infect. Agents Dis. 2:1993;1-16.
3. Pennington JE. Pseudomonas aeruginosa pneumonia and other respiratory tract infections. In: Baltch A, editor. Pseudomonas aeruginosa infections and treatment. New York: Marcel Dekker, 1994. p. 159-81.
4. Gray B.M. Pneumococcal infections in an era of multiple antibiotic resistance. Adv. Pediatr. Infect. Dis. 11:1996;55-99.
5. Tuomanen E.I., Austrian R., Masure H.R. Pathogenesis of pneumococcal infection. N. Engl. J. Med. 332:1995;1280-1284.
6. Rubins J.B., Duane P.G., Clawson D., Charboneau D., Young J., Niewoehner D.E. Toxicity of pneumolysin to pulmonary epithelial cells. Infect. Immun. 61:1993;1352-1358.
7. Benton K., Vancott J.L., Briles D.E. Role of tumour necrosos factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae. Infect. Immun. 66:1998;839-842.
8. Cundell D.R., Gerald N.P., Gerald C., Heikkila I., Tuomanen E. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 377:1995;435-438.
9. Boyle F.M., Georghiou P.R., Tilse M.H., McCormack J.G. Branhamella (Moraxella) catarrhalis: pathogenic significance in respiratory infections. Med. J. Aust. 154:1991;592-596.
10. Verghese A., Roberson D., Kalbfleisch J.H., Sarubbi F. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 34:1990;1041-1044.
11. Klein J.O. Otitis media. Clin. Infect. Dis. 19:1994;823-833.
12. Faden H., Hong J., Murphy T.F. Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media. Infect. Immun. 60:1992;3824-3829.
13. Sethi S., Hill S.L., Murphy T.F. Serum antibodies to outer membrane proteins (OMPs) of Moraxella (Branhamella) catarrhalis in patients with bronchiectasis: identification of OMP B1 as an important antigen. Infect. Immun. 63:1995;1516-1520.
14. Bernstein J.M. Immunologic reactivity in the middle ear in otitis media with effusion. Otolaryngol. Clin. North Am. 24:1991;845-858.
15. Turk D.C. The pathogenicity to Haemophilus influenzae. J. Med. Micro. 18:1984;1-16.
16. Foxwell A.R., Kyd J.M., Cripps A.W. Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol. Mol. Biol. Rev. 62:1998;294-308.
17. Loutit J.S., Tompkins L.S. Restriction enzyme and southern hybridization analysis of Pseudomonas aeruginosa strains from patients with cystic fibrosis. J. Clin. Microbiol. 29:1991;2897-2900.
18. Hla S.W., Hui K.P., Tan W.C., Ho B. Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronshiectasis patients without cystic fibrosis. J. Clin. Microbiol. 34:1996;575-578.
19. Musher D.M., Goree A., Baughn R.E., Birdsall H.H. Immunoglobulin A from bronchopulmonary secretions blocks bactericidal and opsonizing effects of antibody to nontypable Haemophilus influenzae. Infect. Immun. 45:1984;36-40.
20. Michetti P., Mahan M.J., Slauch J.M., Mekalanos J.J., Neutra M.R. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect. Immun. 60:1992;1786-1792.
21. McDermott M.R., Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory and genital tissue. J. Immunol. 122:1979;1892-1898.
22. Husband AJ. Mucosal immune interactions in intestine, respiratory tract and mammary gland. In: Hisar RP, editor. Progress in veterinary microbiology and immunology. Basel: S. Karger, 1985. p. 25-57.
23. Wallace F.J., Clancy R.L., Cripps A.W. An animal model demonstration of enhanced clearance of nontypable Haemophilus influenzae from respiratory tract after antigen stimulation of gut-associated lymphoid tissue. Am. Rev. Respir. Dis. 140:1989;311-316.
24. Kyd J.M., Dunkley M.L., Cripps A.W. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect. Immun. 63:1995;2931-2940.
25. Foxwell AR, Kyd JM, Cripps AW. Characteristics of the immunological response in the clearance of non-typeable Haemophilus influenzae from the lung. Immunol. Cell Biol. 1998;76:323-31.
26. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Sergio G., Abrignani S., Douce G., Magistris M.T.D. Induction of antigen-specific antibodies in vaginal sectretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:1996;974-979.
27. Wu H.-Y., Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine. 16:1997;286-292.
28. Cripps A.W., Dunkley M.L., Clancy R.L., Kyd J.M. Vaccine strategies against Pseudomonas aeruginosa infection in the lung. Behring Inst. Mitt. 98:1997;262-268.
29. Foxwell AR, Kyd JM, Cripps AW. Kinetics of inflammatory cytokines in the clearance of nontypeable Haemophilus influenzae from the lung. Immunol. Cell Biol. 1998;76:556-9.
30. Buret A., Dunkley M.L., Pang G., Clancy R.L., Cripps A.W. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats: roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1α Infect. Immun. 62:1994;5335-5343.
31. Cripps A.W., Dunkley M.L., Clancy R.L. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect. Immun. 62:1994;1427-1436.
32. van Daal G.-J., van't Veen A., So K.L., Mouton J.W., Smit F., van Hal P.T.W., Bergmann K.C., Lachmann B. Oral immunization with polyvalent bacterial lysate and infection with Streptococcus pneumoniae: influence on interferon-gamma and PMN elastase concentrations in murine bronchoalveolar lavage fluid. Int. Arch. Allergy Immunol. 97:1992;173-177.
33. Lehmann D., Coakley K.J., Coakley C.A., Spooner V., Montgomery J.M., Michael A., Riley I.D., Smith T., Clancy R.L., Cripps A.W., Alpers M.P. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. Am. Rev. Respir. Dis. 144:1991;324-330.
34. Clancy R.L., Cripps A.W., Muree-Allen K., Yeung S., Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive pulmonary disease. Lancet. ii:1985;1395-1397.
35. Kyd J.M., Cripps A.W. Modulation of antigen-specific T- and B-cell responses influence bacterial clearance of nontypeable Haemophilus influenzae from the lung in a rat model. Vaccine. 14:1996;1471-1478.
36. Kyd J.M., Cripps A.W. Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infect. Immun. 66:1998;2272-2278.
37. Murphy TF, Kyd JM, John A, Kirkham C, Cripps AW. Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model. J. Infect. Dis. 1998;178:1667-75.
38. Clemens J.D., Harris J.R., Sack D.A., Chakraborty J., Ahmed F., Stanton B.F., Khan M.U., Kay B.A., Huda N., Khan M.R.et al. Field trial of oral cholera vaccines in Bangladesh: results of one year followup. J. Infect. Dis. 158:1988;60-69.
39. Loeb M.R., Smith D.H. Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications. Infect. Immun. 30:1980;709-717.
40. Mitchell M.A., Skowronek K., Kauc L., Goodgal S.H. Electroporation of Haemophilus influenzae is effective for transformation of plasmid but not chromosomal DNA. Nucl. Acids Res. 19:1991;3625-3628.
41. Szostak M.P., Hensel A., Eko F.O., Klein R., Auer T., Mader H., Haslberger A., Bunka S., Wanner G., Lubitz W. Bacterial ghosts: non-living candidate vaccines. J. Biotech. 44:1996;161-170.
42. Hensel A., Stockhofezurwieden N., Petzoldt K., Lubitz W. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. Infect. Immun. 63:1995;3048-3053.
43. Mukkur T.K.S., Walker K.H., Stocker B.A.D. New generation typhoid and non-typhoid Salmonella vaccines. Today's Life Sci. 4:1992;16-23.
44. Schodel F. Recombinant avirulent Salmonellae as oral vaccine carriers. Infection. 20:1992;5-12.
45. Wells J.M., Robinson K., Chamberlain L.M., Schofield K.M., Le Page R.W.F. Lactic acid bacteria as vaccine delivery vehicles. Antonie van Leeuwenkoek; J. Microbiol. Serol. 70:1996;317-330.
46. Wells J.M., Wilson P.W., Norton P.M., Gasson M.J., Le Page R.W.F. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8:1993;1155-1162.
47. Tagliabue A., Boraschi D. Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. Vaccine. 11:1993;594.
48. Khan I.A., Kasper L.H. IL-15 augments CD8+ T-cell-mediated immunity against Toxoplasma gondii infection in mice. J. Immunol. 157:1996;2103-2108.
49. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., Kolsch E., Podlaski F.J., Gately M.K., Rude E. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subcsasses in vivo. Eur. J. Immunol. 25:1995;823-829.